Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VTRS
Upturn stock ratingUpturn stock rating

Viatris Inc (VTRS)

Upturn stock ratingUpturn stock rating
$9.19
Last Close (24-hour delay)
Profit since last BUY3.61%
upturn advisory
Consider higher Upturn Star rating
BUY since 27 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/29/2025: VTRS (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

9 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $11.14

1 Year Target Price $11.14

Analysts Price Target For last 52 week
$11.14 Target price
52w Low $6.75
Current$9.19
52w High $13.19

Analysis of Past Performance

Type Stock
Historic Profit 36.45%
Avg. Invested days 47
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/29/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 10.87B USD
Price to earnings Ratio -
1Y Target Price 11.14
Price to earnings Ratio -
1Y Target Price 11.14
Volume (30-day avg) 9
Beta 0.89
52 Weeks Range 6.75 - 13.19
Updated Date 07/29/2025
52 Weeks Range 6.75 - 13.19
Updated Date 07/29/2025
Dividends yield (FY) 5.10%
Basic EPS (TTM) -3.18

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -26.45%
Operating Margin (TTM) 5.67%

Management Effectiveness

Return on Assets (TTM) 2.23%
Return on Equity (TTM) -21.25%

Valuation

Trailing PE -
Forward PE 4.23
Enterprise Value 24324594986
Price to Sales(TTM) 0.76
Enterprise Value 24324594986
Price to Sales(TTM) 0.76
Enterprise Value to Revenue 1.7
Enterprise Value to EBITDA 11.16
Shares Outstanding 1173680000
Shares Floating 1165642243
Shares Outstanding 1173680000
Shares Floating 1165642243
Percent Insiders 0.26
Percent Institutions 85.18

ai summary icon Upturn AI SWOT

Viatris Inc

stock logo

Company Overview

overview logo History and Background

Viatris Inc. was formed in November 2020 through the merger of Mylan N.V. and Upjohn, a division of Pfizer. Mylan's history dates back to the 1960s as a generic drug manufacturer. Upjohn had a long history as part of Pfizer, focusing on established pharmaceutical brands.

business area logo Core Business Areas

  • Developed Markets: Focuses on developed markets, including North America, Europe, and Australia, selling a wide array of generic and branded pharmaceutical products.
  • Emerging Markets: Targets emerging markets like China, India, and Latin America, selling generic drugs and branded medications to address the unique healthcare needs of these regions.
  • Biosimilars: Develops and commercializes biosimilar versions of complex biologic drugs, offering more affordable treatment options to patients.

leadership logo Leadership and Structure

Viatris is led by a management team with experience from both Mylan and Upjohn. The organizational structure consists of global business units and regional teams, reflecting its global presence.

Top Products and Market Share

overview logo Key Offerings

  • Lipitor (atorvastatin): Lipitor is a branded generic drug for lowering cholesterol. While patent protection has expired, Viatris maintains a significant market share in some regions. Competitors include generic atorvastatin manufacturers and other statin drugs like rosuvastatin (Crestor). Viatris generates a significant portion of its revenue from this product.
  • EpiPen (epinephrine auto-injector): EpiPen is an epinephrine auto-injector used to treat severe allergic reactions (anaphylaxis). Viatris owns the brand name product outside of North America. It faces competition from other epinephrine auto-injectors, including generics and alternatives like Auvi-Q. In some markets it is the dominant product and generates significant revenue for Viatris.
  • Viagra: Viagra is a branded generic drug used to treat erectile dysfunction. While patent protection has expired, Viatris maintains a significant market share in some regions. Competitors include generic sildenafil manufacturers and other ED drugs like Cialis and Levitra. Viatris generates a significant portion of its revenue from this product.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by intense competition, regulatory scrutiny, and ongoing innovation. Generics and biosimilars are increasingly important due to cost pressures on healthcare systems.

Positioning

Viatris is a global pharmaceutical company focused on generic and branded drugs, as well as biosimilars. It aims to provide affordable and accessible medicines worldwide.

Total Addressable Market (TAM)

The global generic drugs market is estimated to be worth hundreds of billions of dollars. Viatris is positioned to capture a significant portion of this market through its extensive product portfolio and global reach.

Upturn SWOT Analysis

Strengths

  • Global presence and distribution network
  • Diverse product portfolio
  • Strong focus on generics and biosimilars
  • Experienced management team

Weaknesses

  • High debt levels
  • Integration challenges from the merger
  • Dependence on key products
  • Complex organizational structure

Opportunities

  • Growth in emerging markets
  • Increasing demand for biosimilars
  • Strategic acquisitions and partnerships
  • Expansion of product portfolio

Threats

  • Intense competition from generic drug manufacturers
  • Pricing pressures and regulatory changes
  • Patent expirations
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • TEVA
  • LCI
  • PRGO
  • PFE

Competitive Landscape

Viatris competes with other generic drug manufacturers, branded pharmaceutical companies, and biosimilar developers. Its strengths include its global scale and diverse product portfolio. Its weaknesses include its debt levels and integration challenges.

Major Acquisitions

Oyster Point Pharma

  • Year: 2023
  • Acquisition Price (USD millions): 425
  • Strategic Rationale: Expands Viatris' ophthalmology portfolio and pipeline, diversifying its product offerings and entering the dry eye disease market.

Growth Trajectory and Initiatives

Historical Growth: Viatris's historical growth trends depends on historical financial data.

Future Projections: Future growth projections depends on analyst estimates.

Recent Initiatives: Viatris is focused on deleveraging its balance sheet, streamlining its operations, and launching new products. They are actively pursuing biosimilar development and expansion into emerging markets.

Summary

Viatris is a global pharmaceutical company with a diverse portfolio of generic and branded drugs. Its strengths include its global scale and focus on affordable medicines. However, the company faces challenges related to debt, integration, and competition. They have undertaken strategic initiatives to focus on key products and markets to improve profitability.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is based on available information and is not financial advice. Market conditions are dynamic and can change rapidly.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Viatris Inc

Exchange NASDAQ
Headquaters Canonsburg, PA, United States
IPO Launch date 2020-11-16
CEO & Director Mr. Scott Andrew Smith Ph.D.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 32000
Full time employees 32000

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.